Crescita Therapeutics Inc.

TSX:CTX 株式レポート

時価総額：CA$11.1m

Crescita Therapeutics マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Serge Verreault

最高経営責任者

CA$462.3k

報酬総額

CEO給与比率81.1%
CEO在任期間7.6yrs
CEOの所有権3.9%
経営陣の平均在職期間データなし
取締役会の平均在任期間8.7yrs

経営陣の近況

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

Oct 25
Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Jan 04
Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Nov 18
Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 10
Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

CEO報酬分析

Crescita Therapeutics の収益と比較して、Serge Verreault の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-CA$3m

Jun 30 2024n/an/a

-CA$3m

Mar 31 2024n/an/a

-CA$2m

Dec 31 2023CA$462kCA$375k

-CA$2m

Sep 30 2023n/an/a

-CA$658k

Jun 30 2023n/an/a

CA$819k

Mar 31 2023n/an/a

CA$1m

Dec 31 2022CA$704kCA$375k

CA$862k

Sep 30 2022n/an/a

CA$627k

Jun 30 2022n/an/a

-CA$468k

Mar 31 2022n/an/a

-CA$1m

Dec 31 2021CA$651kCA$375k

-CA$1m

Sep 30 2021n/an/a

-CA$3m

Jun 30 2021n/an/a

CA$2m

Mar 31 2021n/an/a

CA$95k

Dec 31 2020CA$659kCA$338k

CA$37k

Sep 30 2020n/an/a

CA$146k

Jun 30 2020n/an/a

-CA$4m

Mar 31 2020n/an/a

CA$1m

Dec 31 2019CA$823kCA$336k

CA$2m

Sep 30 2019n/an/a

CA$5m

Jun 30 2019n/an/a

CA$6m

Mar 31 2019n/an/a

CA$3m

Dec 31 2018CA$555kCA$287k

CA$2m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$10m

Mar 31 2018n/an/a

-CA$9m

Dec 31 2017CA$734kCA$173k

-CA$11m

報酬と市場: Sergeの 総報酬 ($USD 330.94K ) は、 Canadian市場 ($USD 169.25K ) の同規模の企業の平均を上回っています。

報酬と収益: Sergeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Serge Verreault

7.6yrs

在職期間

CA$462,268

報酬

Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and its Chief Executive Officer since April 2, 2018 and is Director from June 20, 2023. Mr. Verreault...

取締役

名称ポジション在職期間報酬所有権
Serge Verreault
President1.4yrsCA$462.27k3.87%
CA$ 430.2k
Anthony Dobranowski
Independent Director8.7yrsCA$74.75k0.52%
CA$ 58.0k
John London
Independent Vice Chairman8.7yrsCA$60.75k1.01%
CA$ 112.2k
Daniel Chicoine
Non-Executive Chairman8.7yrsCA$72.25k5.51%
CA$ 613.3k
Deborah Shannon-Trudeau
Independent Non-Executive Director3yrsCA$56.75kデータなし

8.7yrs

平均在職期間

経験豊富なボード: CTXの 取締役会 は 経験豊富 であると考えられます ( 8.7年の平均在任期間)。